Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Thalidomide

Known as: N-Phthalyl-glutaminsaeure-imid, 2,6-Dioxo-3-phthalimidopiperidine, (+-)-Thalidomide 
A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic… Expand
National Institutes of Health

Related topics

Related topics

42 relations

Narrower (18)

3-aminophthalimidoglutarimide5'-hydroxythalidomideConterganDistaval
Expand

Broader (5)

AminesAnalgesicsLeprostatic AgentsPiperidones
Expand
Angiogenesis InhibitionAphthous StomatitisEndothelial CellsErythema Multiforme
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Identification of a Primary Target of Thalidomide Teratogenicity
Thalidomide Teratogenicity Target In the late 1950s and early 1960s, thalidomide was prescribed to pregnant women as a cure for… Expand
Review
2008
Review
2008
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
The incidence of venous thromboembolism (VTE) is more than 1‰ annually in the general population and increases further in cancer… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
2006
Highly Cited
2006
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
BACKGROUND High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. We assessed whether the… Expand
  • figure 1
  • table 2
  • figure 2
  • table 3
Highly Cited
2000
Highly Cited
2000
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Although thalidomide (Thal) was initially used to treat multiple myeloma (MM) because of its known antiangiogenic effects, the… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
1999
Highly Cited
1999
Antitumor activity of thalidomide in refractory multiple myeloma.
BACKGROUND Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options. Since increased bone… Expand
  • table 1
  • figure 1
  • figure 2
Highly Cited
1994
Highly Cited
1994
Thalidomide is an inhibitor of angiogenesis.
Thalidomide is a potent teratogen causing dysmelia (stunted limb growth) in humans. We have demonstrated that orally administered… Expand
Highly Cited
1993
Highly Cited
1993
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
We have examined the mechanism of thalidomide inhibition of lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Highly Cited
1991
Highly Cited
1991
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
Thalidomide selectively inhibits the production of human monocyte tumor necrosis factor alpha (TNF-alpha) when these cells are… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
Highly Cited
1961
Highly Cited
1961
Thalidomide and Congenital Abnormalities
Sir,—Congenital abnormalities are present in approximately 1.5% of babies. In recent months I have observed that the incidence of… Expand
Highly Cited
1947
Highly Cited
1947
DISEASE
  • 1947
    • Corpus ID: 222064452
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE